Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Nonavalent HPV Vaccination in Women Treated for Vulvar HSIL
NCT06052696Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- Mar 2024
- Primary completion
- Dec 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of recombinant human papillomavirus 9-valent vaccine in vulvar squamous intraepithelial lesion (VIN), sponsored by Erasmus MC. Started Mar 2024; status: recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
vulvar squamous intraepithelial lesion (VIN)
Beyond the preview
Go deeper on NCT06052696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06052696.